Fibrinolytic Therapy Versus Medical Thoracoscopy

• Status: Completed
• Trial end date: 2020-02-04
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this prospective randomized clinical trial is to compare two currently accepted standard-of-care treatment strategies: medical thoracoscopy as compared to instillation of intrapleural tissue plasminogen activator (TPA) and human recombinant deoxyribonuclease (DNase) for the management of complicated pleural infections in adults as defined as complicated parapneumonic effusions or pleural empyema.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Florida
• Treatments: Tissue Plasminogen Activator

Criteria

Inclusion Criteria:

1. CPPE along with evidence of septated pleural effusion on pleural ultrasonography and/or chest CT scan

2. empyema.

Exclusion Criteria:

1. age <18 years;

2. Pregnancy

3. inability to give informed written consent;

4. previous thoracic surgery or thrombolytic therapy for pleural infection;

5. medical thoracoscopy cannot be performed within 48 hours;

6. inability to tolerate procedure due to hemodynamic instability or severe hypoxemia;

7. inability to correct coagulopathy;

8. presence of a homogeneously echogenic effusion on pleural US27 -